RT Journal Article
SR Electronic
T1 High Sensitivity and NPV for BinaxNOW Rapid Antigen Test in Children at a Mass Testing Site During Prevalent Delta Variant Period
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.05.22268788
DO 10.1101/2022.01.05.22268788
A1 Sun, Kristie J.
A1 Vaeth, Mary Jane E.
A1 Robinson, Matthew
A1 Elhabashy, Maryam
A1 Gupta, Ishaan
A1 Purekal, Sophia
A1 Hammershaimb, E. Adrianne
A1 Peralta, Ria
A1 Mitchell, Asia
A1 Foyez, Maisha
A1 Johnson, J. Kristie
A1 Ficke, James R
A1 Manabe, Yukari C.
A1 Campbell, James D.
A1 Callahan, Charles W.
A1 Locke, Charles F.
A1 Kantsiper, Melinda
A1 ,
A1 Siddiqui, Zishan K.
YR 2022
UL http://medrxiv.org/content/early/2022/01/20/2022.01.05.22268788.abstract
AB SARS-CoV-2 continues to develop new, increasingly infectious variants, such as delta and omicron. Here, we evaluate the efficacy of the Abbott BinaxNOW Rapid Antigen Test against Reverse Transcription Polymerase Chain Reaction (“RT-PCR”) in 1054 pediatric participants presenting to a state-owned high-volume Coronavirus Disease 2019 (COVID-19) testing site. During the testing period, the delta variant was predominant. Participants were grouped by self-reported COVID-19 exposure and symptom status. RT-PCR results demonstrated an overall prevalence rate of 5.2%. For all participants, the sensitivity of the rapid antigen tests was 92.7% (95% CI 82.4% - 98.0%) and specificity was 98.0% (95% CI 97.0%-98.8%). For symptomatic participants, the sensitivity was 92.3% (95% CI 74.9% - 99.1%), specificity was 96.6% (95% CI 93.6%-98.4%), positive predictive value (PPV) was 72.7% (95% CI 54.5% - 86.7%) and negative predictive value (NPV) was 99.2% (95% CI 98.2% - 100%). Among asymptomatic participants, the sensitivity was 92.6% (95% CI 75.7% - 99.1%), specificity was 98.6% (95% CI 97.5% - 99.3%) the PPV was 71.4% (95% CI 53.7% - 85.4%) and the NPV was 99.7% (95% CI 99.0% - 100%). Our reported sensitivity and NPV are higher than other pediatric studies, potentially because of higher viral load from the more transmissible delta variant, but specificity and PPV are lower.Importance The BinaxNOW rapid antigen COVID-19 test had a sensitivity of nearly 92% in both symptomatic and asymptomatic children when performed at a high-throughput setting during the more transmissible delta variant dominant period. The test may play an invaluable role in asymptomatic screening and keeping children safe in school.Competing Interest StatementDr. Manabe reports institutional grants (to Johns Hopkins) from National Institutes of Health, Becton-Dickinson, Centers for Disease Control, and Baltimore City Health Department and institutional receipt (to Johns Hopkins) of equipment, materials, drugs, medical writing, gifts or other services from Hologic, Becton Dickinson, Roche, Cepheid, and ChemBio. Dr. Robinson reports institutional grants (toJohns Hopkins) from National Institutes of Health, Becton-Dickinson, Centers for Disease Control, and institutional receipt (to Johns Hopkins) of equipment, materials, drugs from Becton Dickinson. All other authors report no conflicts of interests.Clinical Protocols https://journals.asm.org/doi/10.1128/Spectrum.01008-21 Funding StatementThis study did not receive any funding. BinaxNOW test kits were provided by the Maryland Department of Health free of cost.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Johns Hopkins gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are available upon reasonable request to the authors